[SCHEDULE 13G] Apogee Therapeutics, Inc. Passive Investment Disclosure (>5%)
Rhea-AI Filing Summary
The Vanguard Group has disclosed a significant stake in Apogee Therapeutics Inc. As of 12/31/2025, Vanguard reports beneficial ownership of 2,857,824 shares of Apogee common stock, representing 5.21% of the class.
Vanguard reports no sole voting or dispositive power. It has shared voting power over 374,247 shares and shared dispositive power over 2,857,824 shares. The holdings are for clients, who have rights to dividends and sale proceeds, with no single client exceeding 5% of the class.
Vanguard states the shares were acquired and are held in the ordinary course of business, not to change or influence control of Apogee. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies.
Positive
- None.
Negative
- None.